COVID Links
Curated & Updated Daily
XFG, an Omicron sublineage, accounted for 45% of all globally submitted sequences as of March 2026. Meanwhile NB.1.8.1 climbed to 31% of global sequences and is increasing in the Americas and Western Pacific. WHO classifies both under active monitoring with no elevated severity signal.
Source WHO COVID-19 Dashboard [April 2026] — Support for: variant monitoring
The FDA authorized updated 2025–2026 COVID-19 vaccines formulated for currently circulating strains. Three manufacturers offer updated options for everyone 6 months and older, with priority recommended for adults 65+ and those at higher risk. No preference is indicated between products.
Source CDC [April 2026] — Support for: vaccine guidance
Paxlovid remains the most widely available oral antiviral, approved for adults and children 12+ at high risk — must be started within 5 days of symptoms. Remdesivir (Veklury) remains FDA-approved for both hospitalized and high-risk outpatient use. Check with your provider for current eligibility.
Source CDC — COVID-19 Treatment [April 2026] — Support for: treatment options
CDC advises travelers to review current COVID-19 Travel Health Notices before international trips. Recommendations include staying up to date on vaccines, carrying an antiviral prescription if eligible, and monitoring destination-specific transmission levels on the CDC Travelers' Health portal.
Source CDC Travelers' Health [April 2026] — Support for: travel planning